Last reviewed · How we verify
Lidocaine 1% Injectable Solution
Lidocaine 1% Injectable Solution, marketed by the University of Miami, is a well-established anesthetic in the healthcare sector. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk is the loss of market exclusivity post-patent expiry, which could significantly impact revenue.
At a glance
| Generic name | Lidocaine 1% Injectable Solution |
|---|---|
| Also known as | Antiarrythmic drug, Xylocaine 1% |
| Sponsor | University of Miami |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of the Effectiveness of Exercise, Dry Needling and Interfascial Block Treatments in the Treatment of Myofascial Pain Syndrome (NA)
- Subcutaneous Nitroglycerin to Facilitate Trans-radial Access. (PHASE4)
- Using Lidocaine or Dexmedetomidine to Help Control Blood Pressure Spikes From a Tourniquet During Knee Surgery (PHASE2)
- Efficacy of Autologous Conditioned Serum in Temporomandibular Joint Disorder (NA)
- Effects of Dextrose Prolotherapy in Rotator Cuff Disease (NA)
- Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections (PHASE4)
- The Ultrasound-Guided Dextrose Prolotherapy in Ehlers-Danlos Syndrome Patients (PHASE3)
- The Use of Lidocaine Gel Versus Subconjunctival Xylocaine Injection in Pterygium Excision (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lidocaine 1% Injectable Solution CI brief — competitive landscape report
- Lidocaine 1% Injectable Solution updates RSS · CI watch RSS
- University of Miami portfolio CI